Ikena Oncology (IKNA) and clinical-stage biotechnology company Inmagene Biopharmaceuticals said Monday they have agreed to merge that will result in the latter owning about 43.5% of the combined company.
Ikena stockholders will own about 34.8%, and the financing investors some 21.7%, the companies said.
The merged entity intends to operate under the ImageneBio name and trade on Nasdaq under the IMA ticker. It will focus on the development of IMG-007 to treat atopic dermatitis, a skin condition that causes dry, itchy and inflamed skin. The companies said IMG-007's phase 2b clinical trial in atopic dermatitis is expected to start early next year.
Under the terms of the deal, Inmagene shareholders will receive contingent value rights for its non-IMG-007 assets, while Ikena shareholders will receive contingent value rights for the company's legacy pipeline assets.
In connection with the deal, Ikena has signed subscription agreements for a $75 million private placement with a syndicate that includes certain new and existing investors. The board-approved deal is expected to close in mid-2025.
The company's shares were up more than 14% in recent trading.
Price: 1.78, Change: +0.23, Percent Change: +14.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.